Literature DB >> 29984822

Single-nucleotide polymorphisms of VEGF-A and VEGFR-2 genes and risk of infantile hemangioma.

Katarzyna Oszajca1, Janusz Szemraj1, Dariusz Wyrzykowski2, Barbara Chrzanowska2, Aneta Salamon3, Przemyslaw Przewratil3.   

Abstract

BACKGROUND: Infantile hemangioma (IH) is the most common vascular tumor of childhood and infancy. It is distinguished by rapid proliferation of endothelial cells during the first year of life followed by spontaneous regression thereafter. One of the possible factors responsible for the IH development is vascular endothelial grow factor (VEGF). The purpose of this study was to evaluate the influence of selected polymorphisms in the genes coding for VEGF-A (+405 G/C, rs2010963; +936 C/T, rs3025039) and its receptor VEGFR-2 (+1416 T/A, rs1870377; -271 G/A, rs7667298) on the susceptibility to infantile hemangioma.
METHODS: We performed a case-control study of 99 Polish children hospitalized due to IH and compared them with matched healthy control subjects. The polymorphisms were ascertained through genotyping by PCR-RFLP assay, PCR-HRM, or the allelic discrimination method.
RESULTS: The study revealed a lower odds of infantile hemangioma in individuals with GG genotype or G allele for +405 G/C VEGF-A polymorphism (ORdis = 0.52, P = 0.023 and ORdis  = 0.63, P = 0.025, respectively). No association was observed for the remaining VEGF and VEGFR-2 polymorphisms and IH risk.
CONCLUSIONS: In our study, none of the investigated VEGF-A and VEGFR-2 genes polymorphisms was found to be an independent prognostic marker for infantile hemangioma. However, there is evidence that individuals carrying at least one G allele of +405 G/C VEGF-A polymorphism have significantly lower risk of IH.
© 2018 The International Society of Dermatology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29984822     DOI: 10.1111/ijd.14127

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  5 in total

1.  15,16-dihydrotanshinone I inhibits EOMA cells proliferation by interfering in posttranscriptional processing of hypoxia-inducible factor 1.

Authors:  Peiwen Duan; Yingying Huang; Kai Chen; Cheng Cheng; Zhixiang Wu; Yeming Wu
Journal:  Int J Med Sci       Date:  2021-07-11       Impact factor: 3.738

2.  Propranolol inhibits infantile hemangioma by regulating the miR-424/vascular endothelial growth factor-A (VEGFA) axis.

Authors:  Zhen-Bo Wu; Sen-Lin Shi; Feng-Jun Pan; Li Li; Hong-Yu Chen
Journal:  Transl Pediatr       Date:  2021-07

Review 3.  The physiological and pathological functions of VEGFR3 in cardiac and lymphatic development and related diseases.

Authors:  Richard M Monaghan; Donna J Page; Pia Ostergaard; Bernard D Keavney
Journal:  Cardiovasc Res       Date:  2021-07-07       Impact factor: 10.787

Review 4.  Genetic investigation of childhood vascular tumor biology reveals pathways for therapeutic intervention.

Authors:  Shayan Cheraghlou; Young Lim; Keith Choate
Journal:  F1000Res       Date:  2019-04-30

5.  Assessment of the Hematopoietic Differentiation Potential of Human Pluripotent Stem Cells in 2D and 3D Culture Systems.

Authors:  German Atzin Mora-Roldan; Dalia Ramirez-Ramirez; Rosana Pelayo; Karlen Gazarian
Journal:  Cells       Date:  2021-10-23       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.